We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Colin Kellaher U.S.-listed shares of Kazia Therapeutics jumped in premarket trading Thursday after the Australian biotechnology company said the U.S. Food and Drug Administration granted a...
By Colin Kellaher U.S.-listed shares of Kazia Therapeutics Ltd. jumped more than 15% in premarket trading Wednesday after the Australian biotechnology company said the U.S. Food and Drug...
Kazia and Kintara Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With Glioblastoma Kazia’s Paxalisib and Kintara’s VAL-083 to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | -1.295 | -94.1818181818 | 1.375 | 1.48 | 0.051 | 205663 | 0.24243704 | DE |
260 | -0.555 | -87.4015748031 | 0.635 | 1.88 | 0.051 | 199575 | 0.63785431 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions